This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: C4 Therapeutics, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Scott Joseph Eron: Innovator in Cereblon Binding Technologies
Introduction
Scott Joseph Eron is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that interact with cereblon, a crucial component of the E3 ubiquitin ligase complex. His innovative work has implications for targeted protein degradation, which is a promising area in therapeutic development.
Latest Patents
Scott holds a patent for "Bicyclic-substituted glutarimide cereblon binders." This invention provides Degron compounds that bind to cereblon, allowing for the modulation of its activity. The Degrons can be utilized either independently or covalently linked to a Tail. Additionally, these Degrons can be connected to a Targeting Ligand that binds to a Target Protein, facilitating protein degradation.
Career Highlights
Scott is currently employed at C4 Therapeutics, Inc., where he continues to advance his research in the field of protein degradation. His work is pivotal in the development of new therapeutic strategies that leverage the ubiquitin-proteasome system.
Collaborations
Scott collaborates with talented individuals such as Christopher G Nasveschuk and Kiel Lazarski. Their combined expertise enhances the innovative environment at C4 Therapeutics, Inc.
Conclusion
Scott Joseph Eron is a distinguished inventor whose work on cereblon binders is paving the way for advancements in targeted protein degradation therapies. His contributions are vital to the ongoing research and development in this promising field.